[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650215":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":27,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":27,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":27,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":45,"whyStopped":27,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Olanzapine-Based Dexamethasone-Sparing Regimen","EXPERIMENTAL","* Pantoprazole 40 mg PO daily (1 hour before breakfast)\n* Olanzapine 5 mg PO daily (at bedtime)",[13,14],"Drug: Pantoprazole","Drug: olanzapine",{"label":16,"type":17,"description":18,"interventionNames":19},"Dexamethasone-Containing Standard Regimen","ACTIVE_COMPARATOR","* Pantoprazole 40 mg PO daily (1 hour before breakfast)\n* Olanzapine 5 mg PO daily (at bedtime)\n* Dexamethasone 4 mg PO BID (total 8 mg\u002Fday)",[13,14,20],"Drug: Dexamethasone",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Pantoprazole","Administered as 40 mg orally once daily on Days 1 to 3 (1 hour before breakfast) in both arms as standard gastroprotective co-medication to prevent chemotherapy- and corticosteroid-induced gastritis and dyspepsia.",[16,9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"olanzapine","Administered as 5 mg orally once daily at bedtime, Days 1-3, for delayed-phase antiemetic prophylaxis.",[16,9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Dexamethasone","Administered as 4 mg orally twice daily (total 8 mg\u002Fday), Days 1-3, for delayed-phase antiemetic prophylaxis.",[16],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"mohamed younes, B.pharmacy","CONTACT","+201500993053","mohamedyounes93ly@gmail.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Alexandria Main University Hospital","RECRUITING","Alexandria","Alexandria Governorate","21526","Egypt","EG",{"type":52,"coordinates":53},"Point",[54,55],29.91582,31.20176,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":40,"phoneExt":27,"email":41},"mohamed younes",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Mohammed Younus Salih","Resident","100650215","olanzapine-based-dexamethasone-sparing-regimen-for-breast-cancer-patients-with-metabolic-risk-factors-100650215",false,"NCT07743827","Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors","Efficacy of an Olanzapine Based Dexamethasone-sparing Regimen in Breast Cancer Patients With Metabolic-risk Factors: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* Female patients ≥18 years.\n* Stage I-III breast cancer.\n* Scheduled to receive AC chemotherapy.\n* Presence of metabolic risk factors (diabetes, prediabetes, obesity, metabolic syndrome).\n* ECOG performance status ≤2.\n\nExclusion Criteria:\n\n* Recent systemic corticosteroid use.\n* Active nausea or vomiting before chemotherapy.\n* Severe renal or hepatic impairment.\n* Uncontrolled diabetes or hypertension.\n* Psychiatric illness affecting adherence.\n* Pregnancy or lactation.\n* Active infections or inflammatory diseases.\n* Participation in another clinical trial","FEMALE","18 Years","70 Years",{"count":75,"type":76},90,"ESTIMATED","INTERVENTIONAL",[79],"NA","The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.",[82,83,33],"Olanzapine","Breast Cancer",[85,29,86,87],"dexamethasone-sparing regimen","metabolic-risk factors","breast cancer patients","2026-07-29",{"date":90,"type":91},"2026-08-04","ACTUAL",{"date":93,"type":91},"2026-05-10",{"date":95,"type":76},"2027-10-15",{"name":5,"class":6},1]